Author:
Iñiguez C.,Larrodé P.,Mayordomo J. I.,Gonzalez P.,Adelantado S.,Yubero A.,Trés A.,Morales F.
Abstract
Peripheral neuropathy (PN) is the main side effect with cycles of paclitaxel at standard does (175 mg/m2 for 21 days). Administration of a single high-dose paclitaxel (HDP) is novel approach for the treatment of cancer. We have prospectively measured neurotoxicity induced by HDP during a phase I trial. Nineteen patients were treated with escalating doses of paclitaxel by 24-hour infusion. In our study, PN induced by HDP was moderate, reversible, and not dose limiting. Severe PN was seen in patients who had received previous neurotoxic chemotherapy, and caution on the administration of HDP in this setting is warranted. NEUROLOGY 1998;51:868-870
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference10 articles.
1. Schiller JH, Storer B, Tutsch K, et al. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Semin Oncol 1994;21(suppl 8):9-14.
2. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20(suppl 3):1-15.
3. Menopausal estrogen replacement therapy in women with breast cancer
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献